Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3

17 May 2022

Abstract excerpt

Cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome is effectively inhibited by pharmacological inhibitors in primary immune cells ex vivo. Dear Editor, The NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome is an essential inflammation driver linked to multiple human diseases, such as gout or Alzheimer’s disease, but is also the genetic cause for cryopyrin-associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to IL-33, ST2, and ILC Pathways
Share to Inflammasome and immune disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35579347
DOI: 10.1093/rheumatology/keac273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3PMID 35579347Read ↗

The NLRP3 inhibitor MCC950 inhibits IL-1β production in PBMC from 19 patients with Cryopyrin-Associated Periodic Syndrome and in 2 patients with Schnitzler’s SyndromeSemantic proximity Read ↗

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibitionSemantic proximity Read ↗

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibitionSemantic proximity Read ↗

The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunitySemantic proximity Read ↗

Pathogenic NLRP3 mutants forms constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β productionSemantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

[Pathophysiological mechanisms underlying cryopyrin-associated periodic syndromes: genetic and molecular basis and the inflammasome].Semantic proximity Read ↗

The NLRP3 Inflammasome as a Pharmacological TargetSemantic proximity Read ↗

Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndromeSemantic proximity Read ↗

NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.